Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Spotlight Innovation Inc. (STLT)

Add STLT Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Ecomike
Search This Board: 
Last Post: 12/17/2017 1:11:48 PM - Followers: 33 - Board type: Free - Posts Today: 6


Spotlight Innovation Inc. (OTCQB: STLT) specializes in identifying, acquiring and incubating companies
which have unique intellectual property (IP) in the medical sector.
The Company utilizes relationships with the nation’s leading academic and institutional IP developers to
locate promising IP technologies with potential for market share capture.
With their support, development, resources and strategic planning expertise, Spotlight Innovation believes
they can develop IP that will have a positive effect on healthcare.
They intend to partner with proven sector leaders on commercialization once technologies are fully developed.
Verified Company Profile3/29/2016
Contact Info
  • 6750 Western Parkway
    Suite 200-226
    West Des Moines, IA 50266
TLT Security Details
Share Structure
  Market Value1 $9,355,615 a/o Aug 29, 2016
  Authorized Shares 4,000,000,000 a/o Nov 04, 2014
  Outstanding Shares 15,856,974 a/o Aug 02, 2016
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 2,342,931 a/o Aug 02, 2016
  Par Value 0.001
Transfer Agent(s)
VStock Transfer LLC
Shareholders of Record 77 a/o Aug 02, 2016
Security Notes
  • Capital Change=shs increased by 14 for 1 split. Payable upon surrender. Pay date=08/19/2008.
    Capital Change=Stk. Div.=50% Ex-date=04/15/2009. Rec date=03/26/2009. Pay date=04/14/2009.
    Capital Change=shs decreased by 1 for 500 split. Ex-date=12/19/2013.

ZACKs Analyst report issued August 2015


LinkedIn Company Page:

YouTube/Google+ Company:




6750 Westown Pkwy, Suite 200-226
West Des Moines, IA 50266
Phone: 515-274-9087



Spotlight Innovation subsidiary 
Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office

Spotlight Innovation signs 
Memorandum of Understanding (MOU) with Black Swan LLC


Spotlight Innovation signs 
Letter of Intent to Acquire Memcine Pharmaceuticals

Spotlight Innovation 
retains Jerry Cirino as Special Advisor

Spotlight Innovation 
retains Barwicki Investor Relations

Spotlight Innovation
 publishes White Paper “Midwest Universities are Cultivating IP Commercialization Success”

JULY 2014
Spotlight Innovation receives 
$250,000 Line of Credit from Denver Savings Bank

JUNE 2014
Spotlight Innovation
 hires Dr. Hostelley as CFO

JUNE 2014
Spotlight Innovation closes 
equity placement of more than $41M: released to Company under certain specified conditions

JUNE 2014
Share exchange agreement finalized between Celtic Biotech Iowa and Celtic Biotech LTD, completing Celtic Biotech LTD acquisition

APRIL 2014
Spotlight Innovation
 receives $752,325 Line of Credit from Denver Savings Bank, secured by Jared DeVries

MARCH 2014
Celtic Biotech Iowa, Inc., becomes wholly-owned subsidiary of Spotlight Innovation Inc.


AEXP/Spotlight Innovation merger completed


March 10, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa licenses promising therapy for Chronic Kidney Disease

Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa, Inc., entered into an exclusive, world-wide (excluding China) license agreement to develop and market a patent-pending invention related to the treatment of acute and chronic nephropathy, Use of Cardiotoxin for the Treatment of Chronic Kidney Disease (CKD).
Read more…

January 15, 2015
Spotlight Innovation subsidiary Celtic Biotech Iowa granted Patent by the U.S. Patent and Trademark Office

Spotlight Innovation Inc. (OTCQB: STLT) announces that its subsidiary Celtic Biotech Iowa Inc. has been granted U.S. Patent entitled Crotoxin Administration for Cancer Treatment and Pain Relief.  The invention relates to Crotoxin compositions for intravenous administration and methods of use of Crotoxin for the treatment of pain and/or for the treatment of neurologic and neuromuscular disorders.
Read more…

January 6, 2015
Spotlight Innovation signs Memorandum of Understanding (MOU) with Black Swan LLC

Spotlight Innovation Inc. (OTCQB:STLT) announces that it has entered into a Memorandum of Understanding with Black Swan LLC. Under the agreement, Black Swan will assist with activities such as identifying applicable government grants and loans, affecting beneficial changes to the legislative environment, advancing emerging technologies, identifying business partners, and developing new markets, particularly in the government sector.
Read more…

December 16, 2014
Spotlight Innovation announces change of Transfer Agent

Spotlight Innovation Inc. (OTCQB:STLT) announces today that effective December 16, 2014, all communications related to shareholder transactions should be directed to VStock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.
Read more…

December 4, 2014
Celtic Biotech Iowa requests reactivation and transfer of National Drug Code registration

Spotlight Innovation Inc. (OTCQB:STLT) announces that a request was submitted to the Center for Drug Evaluation and Research at the Food and Drug Administration to reactivate and transfer the Celtic Biotech (Ireland) National Drug Code (NDC) registration to Celtic Biotech Iowa Inc. in anticipation of the manufacture and commercialization of a proprietary transdermal delivery gel product.
Read more…

October 14, 2014
Spotlight Innovation signs Letter of Intent to Acquire Memcine Pharmaceuticals

Spotlight Innovation Inc. (OTCQB:STLT) announced that it has signed a Letter of Intent to acquire majority ownership in Memcine Pharmaceuticals Inc., located at the University of Iowa Research Park in Coralville, Iowa. Memcine Pharmaceuticals is developing its Immunoplex™ vaccine platform technology, which is designed to use the body’s own naturally occurring targeting system to deliver vaccine components to immune cells and stimulate a robust response.
Read more…

October 1, 2014
Spotlight Innovation Retains Jerry Cirino as Special Advisor

Spotlight Innovation Inc. (OTCQB: STLT) has hired Jerry Cirino as a Special Advisor to provide business development expertise and to advise the Company on strategic opportunities and transactions.
Read more…

September 24, 2014
Spotlight Innovation Retains Barwicki Investor Relations to Provide Global Investor Relations Program

Spotlight Innovation, Inc. (OTCQB: STLT) announced that it has retained Barwicki Investor Relations, a New York-based investor relations firm, to expand the Company’s strategic investor relations program. Barwicki Investor Relations is providing financial community and media relations, and editorial, consulting and advisory services.
Read more…

August 27, 2014
Spotlight Innovation white paper focuses on evolution of efforts to transform University research into profitable business ventures

Spotlight Innovation, Inc. (OTCQB:STLT) today published a white paper reporting the progress and growth of the transfer and commercialization of university-generated research and intellectual property (IP).
Read more…

August 5, 2014
Spotlight Innovation signs second Letter of Credit with Denver Savings Bank

Spotlight Innovation, Inc. (OTCQB:STLT) has entered into a second Letter of Credit with Denver Savings Bank, located in Denver, Iowa, in the amount of $250,000.00, effective July 29, 2014.
Read more…

July 02, 2014
Spotlight Innovation, Inc., announces closing of financing

Spotlight Innovation, Inc., (OTCQB:STLT) is pleased to announce that it has closed an equity placement of more than $41,418,000 with nine accredited investors, through its equity advisor Catwalk Capital, LLC.
Read more…

June 26, 2014
Spotlight Innovation names Dr. David Hostelley Chief Financial Officer

Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 20, 2014, Dr. David Hostelley has been named Chief Financial Officer of the Company.
Read more…

June 17, 2014
Spotlight Innovation building relationships with Midwest businesses and people

Cristopher Grunewald, President and CEO of Spotlight Innovation said, “The Midwest is a hotbed of talent and innovation, and it has always been a pillar of our business plan to build relationships with people and institutions in the Midwest. We are pleased that we are making good on this commitment.”
Read more…

June 10, 2014
Spotlight Innovation subsidiary Celtic Biotech Iowa, Inc., completes merger with Celtic Biotech Ltd.

Spotlight Innovation, Inc. (OTCQB:STLT) today announced that effective June 4, 2014, Celtic Biotech Iowa, Inc. (a subsidiary of Spotlight Innovation, Inc.) has completed a share exchange agreement with biopharmaceutical company Celtic Biotech Ltd.
Read more…

December, 16, 2013
Spotlight Innovation’s name change, symbol change and reverse split approved by FINRA

Spotlight Innovation, Inc. (“the Company”) (OTCQB:STLT) is pleased to announce that effective December 17, 2013 the Financial Industry Regulatory Authority (“FINRA”) has approved the name change of the company from American Exploration Corp. to Spotlight Innovation, Inc., change of stock symbol to “STLT”, and a 1-500 reverse split of our common stock.
Read more…

December 12, 2013
Spotlight Innovation, Inc. Announces Name Change and Closing of Merger

Spotlight Innovation, Inc. (formerly American Exploration Corporation, AEXP:OTCQB), announced today the completion of a merger with Spotlight Innovation, LLC.
Read more…

Spotlight Innovation is committed to developing quality-of-life-enhancing biotechnologies that have the potential to positively impact the health, well-being and longevity of an enormous number of lives. We are building a portfolio of healthcare/life sciences subsidiary companies, each having the potential to further our commitment.

Celtic Biotech Iowa Inc.

Celtic Biotech, Inc.

Celtic Biotech Iowa Inc., is developing novel therapeutic products for the treatment of cancers and pain in humans. Derived from naturally specialized receptor-binding proteins, these products have the potential to reduce treatment costs, increase survivability, and improve the quality of life for cancer patients.

Celtic Biotech Iowa Inc. is a subsidiary of Spotlight Innovation Inc.

Read the press release here.

Additional information about Celtic Biotech here.

Celtic Biotech Iowa Inc.



Cristopher Grunewald, CEO

Mr. Grunewald is a financial executive and entrepreneur with background in the healthcare and biotechnology sectors, private equity and investment banking. He has been involved in all stages of the commercialization of healthcare IP developed by premiere research and development institutions.

Dr. David Hostelley, CFO

Dr. Hostelley has twenty years as a consultant in the health field, and has served as CEO, CFO and board member of several publicly traded companies. Dr. Hostelley is a CPA (inactive) licensed by the state of Ohio. He earned his Ph.D. in management while a lecturer in the MBA Program of Baldwin-Wallace College, and has lectured in Accounting and Management for Walsh University, North Canton, Ohio.

Jeffrey Stein, Esq., Securities Counsel

Mr. Stein serves as securities counsel for Spotlight Innovation. He has over fifteen years of experience providing high quality, personalized attention to public companies, including more than thirty reverse mergers, IPOs and APOs.

Rene Erickson, Corporate Communications

Mr. Erickson has three decades of corporate communications experience across diverse industries including healthcare, information technology, aviation and academia.

Mike Reysack, Investor Relations

Mr. Reysack leads Investor Relations for Spotlight Innovation. He has extensive experience cultivating and managing relationships with financial stakeholders, including fifteen years as an Investor Relations consultant and business strategist for venture and early stage companies, providing effective communications between companies and the financial community.

Special Advisor

Jerry Cirino

Mr. Cirino is a healthcare technology executive with extensive background in medical devices, distribution and healthcare information in private equity and public environments. His experience includes management of complex growth and transition environments including M&A, integrations and global operations, and he is a proven consultant in transaction evaluation, due diligence and strategic planning.

Partner Firms


GBH CPAs, PC, Houston, TX

Transfer Agent

VStock Transfer, LLC, Woodmere, NY

Law Firms

Davis Brown Law Firm, Des Moines, IA
JMS Law Group, New York, NY
Eilers Law Group, Miami, FL
Whitfield & Eddy, P.L.C., Des Moines, IA


Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#1448  Sticky Note The 8-K filled today by STLT explains this Ecomike 08/30/16 02:59:59 PM
#1806   T-VDAGPRC: bow-tie 12/17/17 01:11:48 PM
#1805   look this bro! bow-tie 12/17/17 01:01:53 PM
#1804   Dr. Greggory Laff: bow-tie 12/17/17 12:56:12 PM
#1803   Institut Pasteur Paris, France Crotoxin Half Century of Investigations. bow-tie 12/17/17 12:36:47 PM
#1802   Crotoxin: 11h30 – 11h50 : Grazyna FAURE bow-tie 12/17/17 12:21:59 PM
#1801   Crotoxin, a phospholipase A2 toxin from the rattlesnake bow-tie 12/17/17 11:48:14 AM
#1800   This is last one Bro!! bow-tie 12/16/17 10:51:42 PM
#1799   Thanks for the efforts this weekend friend Work Harder 12/16/17 10:03:54 PM
#1798   Last Post Bro! We can't! Could Merck Be bow-tie 12/16/17 09:59:24 PM
#1797   A first for the Fda Work Harder 12/16/17 09:51:26 PM
#1796   LMAO Friend! bow-tie 12/16/17 09:45:43 PM
#1795   Merck got a lot riding on this Work Harder 12/16/17 09:44:35 PM
#1794   So, not to be a big mucky muck here Work Harder 12/16/17 09:18:15 PM
#1793   Spotlight Innovation-Celtic Biotech and Butantan Institute bow-tie 12/16/17 09:10:09 PM
#1792   It gets better Work Harder 12/16/17 08:32:40 PM
#1791   WOW/NICE BRO! Think Spotlight Innovation and Butantan Institude-Look bow-tie 12/16/17 08:28:14 PM
#1790   you know I'm serious Work Harder 12/16/17 08:27:12 PM
#1789   without regard to the tissue type or site Work Harder 12/16/17 08:23:26 PM
#1788   Patients in remission after taking lung cancer drug Work Harder 12/16/17 08:20:16 PM
#1787   I'm looking now but not hard Work Harder 12/16/17 08:17:01 PM
#1786   No Chit Work Harder 12/16/17 08:07:47 PM
#1785 bow-tie 12/16/17 07:52:03 PM
#1784   You likie Bro Work Harder 12/16/17 07:41:50 PM
#1783   Several Phase I Human Clinical trials have been Work Harder 12/16/17 07:32:34 PM
#1782   Odd eh Work Harder 12/16/17 07:28:36 PM
#1781 bow-tie 12/16/17 06:21:07 PM
#1780   SaW that ;) Former assistant US surgeon general, bow-tie 12/16/17 06:12:17 PM
#1779   I do to Work Harder 12/16/17 06:04:05 PM
#1778 bow-tie 12/16/17 05:55:11 PM
#1777   I Like It :) The year of the bow-tie 12/16/17 05:38:36 PM
#1776   This is CB24 Work Harder 12/16/17 03:42:10 PM
#1775   The company maintains its own colony of breeding Work Harder 12/16/17 03:09:21 PM
#1774   Great success Work Harder 12/16/17 03:04:23 PM
#1773   Other Study on CB24 And VRCTC-310: VRCTC-310 is bow-tie 12/16/17 12:41:51 PM
#1772   More on Crotoxin: Walker 256 found: In conclusion, bow-tie 12/16/17 12:21:22 PM
#1771   More on SMN: bow-tie 12/16/17 12:01:19 PM
#1770 bow-tie 12/16/17 11:46:17 AM
#1769   Yo gotta be kidin me Work Harder 12/15/17 02:52:24 PM
#1768   Chitra Edwin with Spotlight Innovation worked at Cleveland bow-tie 12/15/17 02:49:51 PM
#1767   This Should be Approved by the FDA Soon. ;) bow-tie 12/15/17 01:50:34 PM
#1766   I wonder what ever happen with this product? bow-tie 12/15/17 01:23:16 PM
#1765   When you talk ole gal which one Bro!! bow-tie 12/15/17 12:43:45 PM
#1764   & get this friend Work Harder 12/14/17 11:06:46 PM
#1763   So, I'm wandering around Work Harder 12/14/17 10:58:50 PM
#1762 bow-tie 12/14/17 09:15:18 PM
#1761   Elliot J. Androphy / University Of Indiana: SMA-Spinal bow-tie 12/14/17 01:10:01 PM
#1760   PHASE 1 VRCTC310 : bow-tie 12/13/17 08:08:23 PM
#1759   VRCTC310: VRCTC310 bow-tie 12/13/17 07:31:33 PM
#1758   VRCTC310 Phase 1: VRCTC-310 is a nat-ural product bow-tie 12/13/17 07:18:14 PM
#1757   BioPark Snakes involved in Studies in Paris, France: bow-tie 12/13/17 06:33:34 PM